Orders from 100 GBP Free delivery from 205 GBP Ready for pickup dead drop: collect in 5 min

Substances · Arylcyclohexylamines

O-DSMT (O-Desmethyltramadol)

C15H23NO2 CAS 80456-81-1 Analytical reference material — not for human consumption
Preferred name
O-DSMT (O-Desmethyltramadol)
IUPAC name
3-[(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol
Parent CAS number (reference)
80456-81-1
Molecular formula
C15H23NO2
Molecular weight
249.35 g/mol
InChIKey
UWJUQVWARXYRCG-HIFRSBDPSA-N
PubChem
CID 9838803
Source
PubChem
Verified synonyms & catalog abbreviations
O-Desmethyltramadol ODSMT O DSMT Desmetramadol

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

O-DSMT (O-Desmethyltramadol)

Mu-Opioid Receptor Agonist & Norepinephrine Reuptake Inhibitor Phenylpropylamine
Verified PubChem & CAS Identity C15H23NO2 · CAS 80456-81-1 · CID 9838803
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 249.35 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

μ-Opioid μ-Opioid Receptor 18 nM

Active M1 metabolite of tramadol: (+)-O-DSMT acts as a selective mu-opioid receptor (MOR Ki = 18 nM) agonist (~200x higher MOR affinity than parent tramadol), while (−)-O-DSMT inhibits norepinephrine reuptake (NET), lacking tramadol's parent SERT bottleneck.

Biotransformation & Active Metabolites

Direct active metabolite; inactivated via UGT2B7/1A8 glucuronidation without requiring CYP2D6 activation.

Temporal Pharmacokinetics

Mu-Opioid Receptor Agonist & Norepinephrine Reuptake Inhibitor — Only opioid-class compound in our substance catalog; unlike parent tramadol, O-DSMT does not depend on CYP2D6 genetics and has minimal SERT activity, but carries full opioid respiratory depression, rapid physical dependence, and lethal interaction risk with benzodiazepines, alcohol, or GHB.

  1. Onset 20–45 min
  2. Peak Window 1.5–3.5 h
  3. Total Window 5–8 h
  4. Residual / Half-Life 4–10 h residual miosis/sedation

Only opioid-class compound in our substance catalog; unlike parent tramadol, O-DSMT does not depend on CYP2D6 genetics and has minimal SERT activity, but carries full opioid respiratory depression, rapid physical dependence, and lethal interaction risk with benzodiazepines, alcohol, or GHB.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
10–15 mg
Cognitive & Sensory

Subtle threshold receptor activity (Mu-Opioid Receptor Agonist & Norepinephrine Reuptake Inhibitor).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
15–30 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
30–55 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
55–85 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
90+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Benzodiazepines (Bromazolam, Etizolam, Clonazolam, Alprazolam)

Profound synergistic respiratory depression and fatal overdose.

Alcohol, GHB/GBL, and Z-drugs

Unconsciousness, respiratory arrest, and fatal pulmonary aspiration.

MAOIs & Potent Stimulants / Dissociatives

NET inhibition plus MAOIs risks hypertensive crisis; dissociatives compound respiratory/aspiration risk.

Elevated Hazard — Avoid

Other opioids or Kratom

Additive mu-opioid respiratory depression and unpredictable toxicity threshold.

Caution / Receptor Attenuation

SNRIs / Tricyclics

Additive noradrenergic tachycardia and blood-pressure elevation.

Structural Isomer & Sibling Comparison

Only opioid-class compound in our substance catalog; unlike parent tramadol, O-DSMT does not depend on CYP2D6 genetics and has minimal SERT activity, but carries full opioid respiratory depression, rapid physical dependence, and lethal interaction risk with benzodiazepines, alcohol, or GHB.

Physicochemical Stability & Storage

Form: White to off-white crystalline analytical powder (hydrochloride salt). · Freely soluble in water and methanol.

Store dry and sealed at room temperature away from light and moisture.

Cross-Tolerance & Dependence Profile

Cross-tolerant with all mu-opioid agonists. High physical and psychological dependence liability; repeated daily exposure produces classic opioid withdrawal syndrome.

Comprehensive Analytical & Toxicological Monograph

O-DSMT (O-Desmethyltramadol) (3-[(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol; CAS 80456-81-1, PubChem CID 9838803) is a phenylpropylamine reference compound (C15H23NO2, 249.35 g/mol) classified pharmacologically as a Mu-Opioid Receptor Agonist & Norepinephrine Reuptake Inhibitor. Active M1 metabolite of tramadol: (+)-O-DSMT acts as a selective mu-opioid receptor (MOR Ki = 18 nM) agonist (~200x higher MOR affinity than parent tramadol), while (−)-O-DSMT inhibits norepinephrine reuptake (NET), lacking tramadol's parent SERT bottleneck. Direct active metabolite; inactivated via UGT2B7/1A8 glucuronidation without requiring CYP2D6 activation. In published observational and toxicological literature, threshold response is noted at 10–15 mg, light range at 15–30 mg, common reference range at 30–55 mg, strong intensity at 55–85 mg, and heavy/adverse territory at 90+ mg, with an onset of 20–45 min, peak window of 1.5–3.5 h, and total duration of 5–8 h (4–10 h residual miosis/sedation). Only opioid-class compound in our substance catalog; unlike parent tramadol, O-DSMT does not depend on CYP2D6 genetics and has minimal SERT activity, but carries full opioid respiratory depression, rapid physical dependence, and lethal interaction risk with benzodiazepines, alcohol, or GHB. Critical contraindications include Benzodiazepines (Bromazolam, Etizolam, Clonazolam, Alprazolam), Alcohol, GHB/GBL, and Z-drugs, MAOIs & Potent Stimulants / Dissociatives.

Chemical Architecture & Structural Profile

O-DSMT (O-Desmethyltramadol) (3-[(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol) is a reference compound belonging to the Arylcyclohexylamines class, characterized by the molecular formula C15H23NO2 and a molar mass of 249.35 g/mol. The parent molecule is indexed under CAS registry number 80456-81-1 and in the NCBI PubChem database as CID 9838803 (Standard InChIKey: UWJUQVWARXYRCG-HIFRSBDPSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), O-DSMT (O-Desmethyltramadol) is indexed within the Phenylpropylamine structural group. Toxicological notes (PsychonautWiki): moderate potential toxicity relative to its dose due to its potency, potentially lethal when mixed with depressants like alcohol or benzodiazepines. Dependence liability (PsychonautWiki): moderately addictive with a high potential for abuse. Documented cross-tolerance class: opioids. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

Uncertain combinations (caution advised)